research Clomiphene Citrate as Nanomedicine Assistance in Ovulatory Disorders and Its Hyphenated Techniques
Nanotechnology improves Clomiphene citrate's effectiveness and reduces side effects for treating ovulatory disorders.
Search
for
Sort by
Research
180-210 / 1000+ results research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Eupafolin nanoparticles protect HaCaT keratinocytes from particulate matter-induced inflammation and oxidative stress
Eupafolin nanoparticles help protect skin cells from damage caused by air pollution.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Exploring the therapeutic potential of Selaginella doederleinii extract for cervical cancer treatment through network pharmacology and in vitro studies
Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.
research Effect of Escin in Human Hair Follicular Organ Culture: Prolonged Anagen Phase
Escin helps keep hair follicles in the growth phase longer.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research The Potential Application of Ecklonia cava Extract in Scalp Protection
Ecklonia cava extract may protect the scalp from pollution and improve its health.
research Pharmacological activities of Eclipta alba (L.) Hassk. (Bhringaraja): A Review
Bhringaraja is a herb with many health benefits, including liver protection, hair growth, pain relief, and more.
research A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research Epidermal E-Cadherin Dependent β-Catenin Pathway Is Phytochemical Inducible and Accelerates Anagen Hair Cycling
A form of vitamin E promotes hair growth by activating a specific skin pathway.
research 52790 Estetrol (E4) prolongs anagen ex vivo: Does E4 have the potential as novel strategy to treat female pattern hair loss?
Estetrol (E4) may help treat female pattern hair loss by prolonging hair growth.
research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Ritlecitinib may help treat alopecia areata by protecting hair follicles.
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Colocalization of Cystatin M/E and its Target Proteases Suggests a Role in Terminal Differentiation of Human Hair Follicle and Nail
Cystatin M/E helps in the final stages of hair and nail formation by controlling certain enzymes.
research A Phytopharmacological Review of Prospective of Bhrungaraj (Eclipta alba Hassk.)
Bhrungaraj (Eclipta alba) shows potential for drug development based on its traditional uses and pharmacological evidence.
research DESIGN OF A VALIDATED HPTLC METHODOLOGY FOR THE MEASUREMENT OF LINOLEIC AND OLEANOLIC ACID IN ECLIPTA ALBA
The HPTLC method is effective and accurate for measuring linoleic and oleanolic acid in Eclipta alba.
research 1409 Temporary cell cycle arrest by ALRN-6924: A novel, p53-targeting strategy to protect human scalp hair follicles against cyclophosphamide-induced alopecia
ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
research 085 Coordinate expressions of cyclin-dependent kinase inhibitors and high sulfur protein in human hair follicles
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Bimatoprost
research Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
research Pretreatment of epidermal growth factor promotes primary hair recovery via the dystrophic anagen pathway after chemotherapy‐induced alopecia
Epidermal growth factor helps hair recover after chemotherapy.
research The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
Erlotinib can cause unexpected side effects like eyelash growth and scarring.
research The Thyroid Hormone Analogue KB2115 (Eprotirome) Prolongs Human Hair Growth (Anagen) Ex Vivo
KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®)
Oclacitinib maleate successfully treated alopecia in Andean bears.
research Pretreatment with epidermal growth factor promotes primary hair recovery in the chemotherapy-induced alopecia
Epidermal growth factor helps hair regrow after chemotherapy.
research Encephalocraniocutaneous lipomatosis: congenital alopecia treatment in a rare neurocutaneous syndrome
A girl with a rare syndrome had successful hair loss treatment with no relapse after 4 years.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.